ZEALAND PHARMA A/S (22Z.DE) Stock Overview
Europe - FRA:22Z - DK0060257814 - Common Stock
22Z.DE Key Statistics, Chart & Performance
The current stock price of 22Z.DE is 68.22 EUR.
22Z.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 21.71 | 346.25B | ||
| 1AMGN.MI | AMGEN INC | 13.65 | 136.64B | ||
| AMG.DE | AMGEN INC | 13.64 | 136.47B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.7 | 120.41B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 24.18 | 89.54B | ||
| ARGX.BR | ARGENX SE | 92.74 | 41.78B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.68B | ||
| IDP.DE | BIOGEN INC | 9.92 | 19.84B | ||
| 0QF.DE | MODERNA INC | N/A | 9.31B | ||
| 1MRNA.MI | MODERNA INC | N/A | 9.08B | ||
| ABVX.PA | ABIVAX SA | N/A | 5.89B | ||
| 2X1.DE | ABIVAX SA | N/A | 5.57B |
Related stock screener links
About 22Z.DE
Company Profile
Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Company Info
ZEALAND PHARMA A/S
Sydmarken 11
Soeborg DK
Employees: 424
Phone: 4588773600
ZEALAND PHARMA A/S / 22Z.DE FAQ
What is the stock price of ZEALAND PHARMA A/S today?
The current stock price of 22Z.DE is 68.22 EUR. The price increased by 1.91% in the last trading session.
What is the ticker symbol for ZEALAND PHARMA A/S stock?
The exchange symbol of ZEALAND PHARMA A/S is 22Z and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 22Z.DE stock listed?
22Z.DE stock is listed on the Deutsche Boerse Ag exchange.
What is the price forecast or stock price prediction for ZEALAND PHARMA A/S stock?
24 analysts have analysed 22Z.DE and the average price target is 109.28 EUR. This implies a price increase of 60.19% is expected in the next year compared to the current price of 68.22. Check the ZEALAND PHARMA A/S stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ZEALAND PHARMA A/S worth?
ZEALAND PHARMA A/S (22Z.DE) has a market capitalization of 3.15B EUR. This makes 22Z.DE a Mid Cap stock.
How many employees does ZEALAND PHARMA A/S have?
ZEALAND PHARMA A/S (22Z.DE) currently has 424 employees.
What are the support and resistance levels for ZEALAND PHARMA A/S (22Z.DE) stock?
ZEALAND PHARMA A/S (22Z.DE) has a support level at 58.9. Check the full technical report for a detailed analysis of 22Z.DE support and resistance levels.
Is ZEALAND PHARMA A/S (22Z.DE) expected to grow?
The Revenue of ZEALAND PHARMA A/S (22Z.DE) is expected to grow by 11614.8% in the next year. Check the estimates tab for more information on the 22Z.DE EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ZEALAND PHARMA A/S (22Z.DE) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 22Z.DE, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 22Z.DE, evaluating the profitability, health, valuation and growth aspects
- ZEALAND PHARMA A/S (22Z.DE) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ZEALAND PHARMA A/S (22Z.DE) Sales and EPS estimates to see what analysts future expectations are.
- ZEALAND PHARMA A/S (22Z.DE) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ZEALAND PHARMA A/S (22Z.DE) Insider and Institutional Ownership to learn about the owners and their transactions.
- ZEALAND PHARMA A/S (22Z.DE) Stock Chart to make your own analysis
- ZEALAND PHARMA A/S (22Z.DE) Latest news and press-releases to stay up to date.
Does ZEALAND PHARMA A/S (22Z.DE) stock pay dividends?
22Z.DE does not pay a dividend.
When does ZEALAND PHARMA A/S (22Z.DE) report earnings?
ZEALAND PHARMA A/S (22Z.DE) will report earnings on 2025-11-13, before the market open.
What is the Price/Earnings (PE) ratio of ZEALAND PHARMA A/S (22Z.DE)?
The PE ratio for ZEALAND PHARMA A/S (22Z.DE) is 5.36. This is based on the reported non-GAAP earnings per share of 12.72 and the current share price of 68.22 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 22Z.DE.
22Z.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to 22Z.DE.
22Z.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 22Z.DE. 22Z.DE has an excellent financial health rating, but there are some minor concerns on its profitability.
22Z.DE Financial Highlights
Over the last trailing twelve months 22Z.DE reported a non-GAAP Earnings per Share(EPS) of 12.72. The EPS increased by 921.54% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 73.34% | ||
| ROA | 38.89% | ||
| ROE | 42.8% | ||
| Debt/Equity | 0.02 |
22Z.DE Forecast & Estimates
24 analysts have analysed 22Z.DE and the average price target is 109.28 EUR. This implies a price increase of 60.19% is expected in the next year compared to the current price of 68.22.
For the next year, analysts expect an EPS growth of 638.53% and a revenue growth 11614.8% for 22Z.DE